DA Davidson upgraded shares of USANA Health Sciences (NYSE:USNA - Free Report) to a hold rating in a research note issued to investors on Friday,Zacks.com reports.
Separately, StockNews.com upgraded shares of USANA Health Sciences from a "buy" rating to a "strong-buy" rating in a research note on Thursday.
Read Our Latest Research Report on USANA Health Sciences
USANA Health Sciences Price Performance
USANA Health Sciences stock traded down $1.33 during midday trading on Friday, reaching $33.38. 619,779 shares of the company traded hands, compared to its average volume of 84,047. USANA Health Sciences has a 12 month low of $33.28 and a 12 month high of $54.81. The business has a 50 day moving average of $37.91 and a two-hundred day moving average of $40.37. The firm has a market capitalization of $636.22 million, a price-to-earnings ratio of 11.80, a price-to-earnings-growth ratio of 1.25 and a beta of 0.89.
USANA Health Sciences (NYSE:USNA - Get Free Report) last released its quarterly earnings results on Tuesday, October 22nd. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.07. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The firm had revenue of $200.22 million for the quarter, compared to analysts' expectations of $208.45 million. During the same period in the prior year, the firm earned $0.59 EPS. As a group, equities analysts forecast that USANA Health Sciences will post 2.45 EPS for the current year.
Insider Transactions at USANA Health Sciences
In other news, Director Gilbert A. Fuller sold 675 shares of the stock in a transaction on Monday, November 4th. The shares were sold at an average price of $37.71, for a total value of $25,454.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.33% of the company's stock.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the company. Bank of New York Mellon Corp boosted its stake in USANA Health Sciences by 5.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 97,375 shares of the company's stock worth $4,405,000 after purchasing an additional 5,205 shares during the period. Panagora Asset Management Inc. increased its holdings in USANA Health Sciences by 143.1% in the 2nd quarter. Panagora Asset Management Inc. now owns 28,881 shares of the company's stock valued at $1,307,000 after acquiring an additional 16,999 shares during the last quarter. Rhumbline Advisers lifted its stake in USANA Health Sciences by 7.1% in the 2nd quarter. Rhumbline Advisers now owns 36,486 shares of the company's stock worth $1,651,000 after purchasing an additional 2,425 shares in the last quarter. Pzena Investment Management LLC boosted its holdings in shares of USANA Health Sciences by 24.4% during the 2nd quarter. Pzena Investment Management LLC now owns 976,633 shares of the company's stock valued at $44,183,000 after purchasing an additional 191,289 shares during the last quarter. Finally, TD Asset Management Inc grew its position in shares of USANA Health Sciences by 26.4% during the second quarter. TD Asset Management Inc now owns 11,500 shares of the company's stock valued at $520,000 after purchasing an additional 2,400 shares in the last quarter. Hedge funds and other institutional investors own 54.25% of the company's stock.
USANA Health Sciences Company Profile
(
Get Free Report)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Further Reading
Before you consider USANA Health Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and USANA Health Sciences wasn't on the list.
While USANA Health Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
